Diligence memo · auto-generated · as of July 3, 2026
Ikano Therapeutics Inc.
Ikano Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ikano Therapeutics Inc. operates in Pharmaceuticals, based in SADDLE BROOK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ikano Therapeutics Inc. has raised $893K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $893K on 2009-11-25.
Most recent recorded round closed around 2009-11-25.
Valuation (modeled)modeled
Provath models Ikano Therapeutics Inc. at approximately $42M (range $500K–$479M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.55× the median modeled value of Pre-Seed Pharmaceuticals companies in 2007–2009 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 16.6 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 18% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: Entopica Therapeutics, Inc., Pneumoflex Systems Llc, Anterion Therapeutics, Inc., Aiko Biotechnology Inc, Ligon Discovery, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.